$MET — BUY 📊 | 6 MONTHS THESIS

$MET — BUY 📊 | 6 MONTHS THESIS 🎯 Q1 2026 | Rev $19.1B | EPS $2.42 vs $2.27 🟢 💡 Consensus expects variable investment income to mean-revert and modest core growth, keeping the stock at a depressed 9x P/E. Our variant view is that elevated investment income is partially structural due to higher-yielding assets, and combined with strong underwriting, MetLife will deliver earnings above $10/sh annually, driving a multiple... 📉 Reward/risk: 2.53:1 🏢 Business Quality: 7/10 📊 Valuation: cheap 🔮 Catalyst: Earnings beat and subsequent upward estimate revisions 💰 Entry: $87.4, stop $84, target $96 ⚖️ Buy MetLife: post-beat valuation disconnect at 9x P/E with multiple expansion catalysts sets up a 2.5:1 reward-to-risk trade toward $96 within three months. 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/MET0617

🎯 Q1 2026 | Rev $19.1B | EPS $2.42 vs $2.27 🟢